Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

Health and Quality of Life Outcomes, Nov 2010

Background Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA. Methods 197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale [FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after start of GA treatment. Results At 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient group (p < 0.001), not in the pre-treated group. At month 12 43% of treatment-naïve patients had improved HR-QoL (increase LMS-QoL score 3 or more points) (p < 0.001). Likewise, mean FIS scores were decreased at months 6 and 12 in the treatment-naïve group (p < 0.01), not in the pre-treated group. In both groups mean BDI-SF scores did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients). Conclusions In RRMS patients without prior immunomodulation/immunosuppression treatment with GA was associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10 patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://www.hqlo.com/content/pdf/1477-7525-8-133.pdf

Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

Health and Quality of Life Outcomes Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study Peter J Jongen 0 Dirk Lehnick 2 Evert Sanders 1 Pierette Seeldrayers 6 Sten Fredrikson 5 Magnus Andersson 4 Joachim Speck 3 FOCUS study group 0 MS4 Research Institute , Ubbergseweg 34, 6522 KJ Nijmegen , the Netherlands 1 Amphia Hospital , Breda , the Netherlands 2 STATPROC , Hohentengen am Hochrhein , Germany 3 Nuvisan GmbH , Neu-Ulm , Germany 4 Karolinska Universitetssjukhuset i Solna , Solna , Sweden 5 Division of Neurology Huddinge, Department of Clinical Neuroscience, Karolinska Institutet , Stockholm , Sweden 6 Hospital Civil de Charleroi , Charleroi , Belgium Background: Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA. Methods: 197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale [FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after start of GA treatment. Results: At 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient group (p < 0.001), not in the pre-treated group. At month 12 43% of treatment-nave patients had improved HRQoL (increase LMS-QoL score 3 or more points) (p < 0.001). Likewise, mean FIS scores were decreased at months 6 and 12 in the treatment-nave group (p < 0.01), not in the pre-treated group. In both groups mean BDI-SF scores did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients). Conclusions: In RRMS patients without prior immunomodulation/immunosuppression treatment with GA was associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10 patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue. - Introduction The efficacy of the disease modifying drug (DMD) glatiramer acetate (GA) in reducing relapses in relapsing remitting multiple sclerosis (RRMS) has been demonstrated in randomized placebo-controlled trials [1,2]. Studies on the effectiveness of GA treatment in daily neurological practice have concentrated on relapses, disability, fatigue [3-5], work absenteeism [4] and costeffectiveness [6,7]. Health-related quality of life (HR-QoL) is an overall measure of effectiveness from a patients perspective and is becoming increasingly important in the assessment of therapies in chronic disorders. It has been demonstrated that in MS patients treatment with the DMD interferonbeta (INFb) is associated with an increase in HR-QoL [8,9]. Data on HR-QoL during GA treatment are scarce and not informative [8,10]. Fatigue and depression are primary determinants of impaired HR-QoL in MS [11]. Fatigue is reported by over 80% of patients [12] and often interferes with social or occupational activities [13]. It has been suggested that GA may improve MS-related fatigue [3,4]. Depressive Table 1 Demographic and neurological characteristics of patient groups 1.15 (0.62) 1.13 (0.50) symptoms are also frequent in MS, the life-time prevalence of major depressive disorders being 22% [14]. To investigate the overall benefit RRMS patients perceive from GA treatment we performed a prospective, observational, international, multi-centre study in patients treated with GA in daily practice, focusing on HR-QoL, fatigue, and depression (FOCUS study). Two groups were studied, patients with prior immunomodulation/immunosuppression (pre-treated group) and patients without such treatment (treatment-nave group) [15]. Here we report the results. Methods Study and study populations Investigator-initiated, prospective, observational, international, multi-centre study. Patients were recruited in out-patient departments from general hospitals, academic hospitals and MS centers in the Netherlands, Sweden and Belgium. The protocol was submitted to the Independent Review Board (IRB), an approved ethical committee residing in Amsterdam, the Netherlands. The IRB concluded that, because of the observational design of the study, a review by an ethical committee was not required. The study did not qualify for being tested according to the Dutch Medical Research Involving Human Subjects Act of 1999 [16]. Patients signed an informed consent form before any study related procedure was performed. The study was carried out in compliance with the Helsin (...truncated)


This is a preview of a remote PDF: http://www.hqlo.com/content/pdf/1477-7525-8-133.pdf

Peter J Jongen, Dirk Lehnick, Evert Sanders, Pierette Seeldrayers, Sten Fredrikson, Magnus Andersson, Joachim Speck, . Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study, Health and Quality of Life Outcomes, 2010, pp. 133, 8, DOI: 10.1186/1477-7525-8-133